このエントリーをはてなブックマークに追加
ID 31714
JaLCDOI
FullText URL
Author
Kawada, Kazuhiko
Yonei, Toshiro
Ueoka, Hiroshi
Takigawa, Nagio
Harada, Mine
Abstract

When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.

Keywords
chemosensitivity test
3-(4
5-dimethylthiazol-2-yl)-2
5-diphenyltertrazolium bromide (MTT) assay
clonogenic assay
Amo Type
Article
Published Date
2002-06
Publication Title
Acta Medica Okayama
Volume
volume56
Issue
issue3
Publisher
Okayama University Medical School
Start Page
129
End Page
134
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT